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angiogenic growth factors are administered to ischemic
tissue to enhance the development of new and collateral
blood vessels.
Studies in which animal models of hindlimb ischemia
were used have shown increased capillary density, vasodi-
latation of existing collateral arteries, or improved resting
muscle perfusion after repeated intramuscular injections of
endothelial cell growth factor,1,2 basic fibroblast growth
factor (bFGF),3,4 and vascular endothelial growth factor
(VEGF).5,8 These injections occurred after intravenous
bolus6 or continuous arterial infusion7 of VEGF and after
administration of VEGF DNA by way of complementary
DNA plasmid10,11 or adenovirus-mediated gene transfer.12
This laboratory has established a model of persistent
hindlimb ischemia.13 Ligation and division of the com-
mon iliac artery led to a significant decrease in ankle blood
pressure that persisted for 38 days, a significant increase in
femoral arterial-venous oxygen difference that persisted
for 24 days, and a significant decrease in limb muscle per-
fusion, as measured by radiolabeled microspheres, that
persisted for 7 days.13 A well-perfused muscle flap was
transposed onto the limb after ipsilateral common iliac
artery ligation and division. Connections between the
Successful treatment of chronic ischemia results in
improved limb function. Unfortunately, therapeutic
options for patients with severe lower extremity arterial
occlusive disease are limited. The preferred treatment is
surgical bypass grafting. However, patients without a
patent distal macroartery for reconstruction will eventually
require limb amputation. 
Alternative methods of revascularization have been
studied. These include therapeutic angiogenesis, in which
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BASIC RESEARCH STUDIES
Functional outcome of new blood vessel growth
into ischemic skeletal muscle 
Steven L. Lee, MD,a William C. Pevec, MD,a and Richard C. Carlsen, PhD,b Sacramento and Davis, Calif
Purpose: The administration of angiogenic growth factors and the transfer of well-vascularized tissues have been shown
to induce development of new blood vessels in ischemic muscle. The functional significance of these new vessels is
unknown. The hypothesis of this study is that the transfer of vascularized muscle and the local infusion of basic fibrob-
last growth factor (bFGF) synergistically improve contractile function of ischemic skeletal muscle.
Methods: Twenty-six rabbits were divided into four groups. An ischemic hindlimb was created in each by ligating the
right common iliac artery. The flap + bFGF group (n = 6) had transposition of a contralateral rectus muscle flap onto
the thigh. Additionally, bFGF (3 ng/h) was continuously infused at the flap-thigh interface. In the flap group (n = 6),
a similar muscle flap was created, but carrier solution was infused at the interface. In the bFGF group (n = 6), no mus-
cle flap was created; instead, bFGF (3 ng/h) was infused into the external iliac artery of the ischemic limb. In the con-
trol group (n = 8), carrier solution was infused into the external iliac artery (no flap, no bFGF). After 1 week, the
soleus muscle was isolated and stimulated. Maximum twitch tension, the fatigue index (force of contraction after 2 min-
utes of continuous stimulation/initial force of contraction), maximum recovery, and the number of limbs recovered (ie,
limbs that achieve a force of contraction during the recovery period of > 75% of the force of the initial contraction at
the start of continuous stimulation) were recorded. Blood vessel density (number of vessels per •••) was determined by
immunostaining the soleus muscle with anti–α-actin antibody.
Results: All values were indexed to the contralateral normal limb. The flap + bFGF group showed significant improve-
ment versus the control group in maximum twitch tension (1.07 ± 0.13 vs 0.63 ± 0.12, P < .05), maximum recovery
(0.94 ± 0.05 vs 0.58 ± 0.05, P < .05), and the number of limbs recovered (5/5 vs 0/6, P < .05). This improved func-
tion correlated with increased vessel density (flap + bFGF group, 1.44 ± 0.11 vs control group, 0.72 ± 0.01, P < .05). 
Conclusion: Reperfusion of an ischemic limb with a well-vascularized muscle flap and local bFGF infusion promoted
increased blood vessel density in distal ischemic muscle. This increased vascularity was associated with restoration of
otherwise impaired muscle function. Improved function occurred rapidly (1 week). A transposed muscle flap provided
a functional blood supply to the site of maximum ischemia; this could be used to salvage otherwise nonreconstructible
ischemic limbs. (J Vasc Surg 2001;34:1096-102.)
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artery of the flap and the native circulation of the ischemic
limb were demonstrated angiographically after 7 days;
these connections were associated with a 45% increase in
the resting muscle perfusion of the limb.14 The results of
a histologic examination demonstrated no blood vessels at
the interface between the flap and the limb muscle at 3
days. Vessels were identified at this interface after 7 and 14
days, and these were confirmed to be new, proliferating
vessels by staining with proliferating cell nuclear antigen.15
Infusion of bFGF at a rate of 3 ng/h for 7 days, at the
interface between the muscle flap and the ischemic limb,
led to a 100% increase in the concentration of new blood
vessels at this interface.16
As described above, other investigators have evaluated
various methods of delivering angiogenic growth factors to
ischemic limbs, to enhance collateral development and
improve resting limb perfusion.1-10,12 None of these stud-
ies has assessed function of the ischemic limb.
Documentation of improved function is necessary before
such techniques can be considered useful clinically.
Furthermore, no other laboratory has evaluated the com-
bination of tissue transfer (which alone can improve the
perfusion of an ischemic limb) with the delivery of angio-
genic growth factors. The current study is designed to
compare function of an ischemic limb, as assessed by distal
muscle strength and resistance to fatigue, after intra-arter-
ial delivery of bFGF versus the combination of tissue trans-
fer and local delivery of bFGF. The hypothesis of this study
is that indirect revascularization with a transposed muscle
pedicle flap and local infusion of bFGF will synergistically
improve function of ischemic skeletal muscle and that this
method of revascularization results in better limb function
compared with simple intra-arterial bFGF infusion.
MATERIALS AND METHODS
Animal model. This study was approved by the
Animal Use and Care Administrative Advisory Committee
of the University of California, Davis, and the guidelines
of the National Institutes of Health’s Guide for the Care
and Use of Laboratory Animals (NIH Publication #86-23,
revised 1985) were followed. Twenty-six New Zealand
white rabbits were anesthetized with a subcutaneous injec-
tion of 0.5 mg/kg acepromazine, 5 mg/kg xylazine, and
50 mg/kg ketamine. Hindlimb blood pressures were
determined by means of a pulse sensor on the hindfoot
(RTBP096; Kent Scientific Corporation, Litchfield,
Conn). The systolic arterial pressure was determined to be
the cuff pressure at which a pulsatile waveform reappeared
while a pediatric blood pressure cuff on the calf was
deflated.
In both the flap + bFGF and flap groups (n = 6, each),
the proximal right common iliac artery was ligated and
transected via a midline laparotomy (Fig 1). An abdominal
muscle flap based on the left deep inferior epigastric artery
was developed; the terminal arborization of this artery
determined the distal edge of the flap. The flap measured
approximately 2 × 10 cm. Viability was confirmed with a
Wood’s lamp after intravenous injection of 1 mL of 10%
Fig 1. Schematic diagram of transposing contralateral rectus
muscle flap onto thigh of ischemic limb.
Fig 2. Diagram of intra-arterial infusion of bFGF into external
iliac artery after common iliac artery ligation.
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fluorescein; all nonfluorescent muscle was debrided. A 3-
cm incision was made in the medial right thigh, and the
left epigastric muscle flap was passed through a subcuta-
neous tunnel and sutured onto the anteromedial surface of
the right gracilis and rectus femoris muscles, directly
superficial to the femoral artery and vein. A miniosmotic
infusion pump (Alza model 2ML2; Alza Corp, Palo Alto,
Calif) was secured to the psoas muscle. A polyethylene
catheter (PE-60; Fisher Scientific, Santa Clara, Calif)
extended from the pump to the interface between the
muscle flap and the muscle of the right thigh. The abdom-
inal muscles were reapproximated at the midline.
The six animals in the flap + bFGF group underwent
infusion, by means of the miniosmotic pumps, of 0.6 µg
recombinant human bFGF (cat. no. 13256-029; Gibco,
Grand Island, NY) in 2-mL phosphate-buffered saline
(PBS) with 0.1% bovine serum albumin (BSA) at a rate of
10 µL/h (3 ng of bFGF per hour) for 7 days. The bFGF
has been shown to retain its biological activity when
stored in microcapsules at 37°C for up to 4 weeks.17 The
six animals in the flap group had only the carrier solution
(PBS with 0.1% BSA) infused at 10 µL/h for 7 days.
In the bFGF and control groups, a similar midline
laparotomy was performed. Miniosmotic pumps were
secured to the psoas muscle. A polyethylene catheter,
which extended from the pump, was inserted into an arte-
riotomy in the proximal right common iliac artery and the
tip positioned in the proximal external iliac artery. The
right common iliac artery was ligated proximal and distal
to the arteriotomy to occlude the common iliac artery and
secure the catheter in place (Fig 2). In the bFGF group,
six animals underwent infusion of bFGF (3 ng/h for 7
days) into the right external iliac artery. In the control
group, eight animals were infused with PBS with 0.1%
BSA into the right external iliac artery (Table I).
Muscle stimulation. At day 7, posture of the
hindlimb at rest and during hopping was evaluated. The
animals were reanesthetized with acepromazine (0.5
mg/kg), xylazine (5 mg/kg), and ketamine (50 mg/kg),
and hindlimb blood pressures were measured. General
anesthesia was maintained with the administration of 1%
to 2% halothane via a tracheotomy. The soleus muscle was
isolated, maintaining its neurovascular pedicle. All muscles
except the soleus were transected proximal to the Achilles
tendon. A number of 3.2-mm threaded Steinman pins
(MicroAire Surgical Instruments, Charlottesville, Va) were
placed transversely through the distal femur and the tarsal
bones of the foot, and used to stabilize the hindlimb with
steel clamps during muscle stimulation. The Achilles ten-
don was divided and attached to a force transducer (Force-
Displacement transducer, model FT-10; Grass Instrument
Co, Quincy, Mass). Needle electrodes (Grass Instrument
Co) were placed 1 cm from the proximal and distal ends
of the soleus muscle for electrical stimulation. The muscle
was coated with mineral oil and petroleum jelly to prevent
desiccation. A needle temperature probe and heat lamp
were used to maintain the muscle temperature between
36.5°C and 37°C (Fig 3).
Isometric contraction and resistance to fatigue in
response to muscle stimulation were assessed. Muscle
length was adjusted to produce 100 g of preload. The
muscle was stimulated with square pulses 0.2 ms in dura-
tion (Grass stimulator, model S48; Grass Instrument Co),
and the tension produced was measured by the force
transducer. The signal was amplified (Macintosh Bridge
Amplifier; Apple Computer, Inc, Cupertino, Calif) and
converted from analog to digital (Macintosh MacLab/8E
A/D Converter) before being recorded by a Power
McIntosh 6100160 computer. Voltage of stimulation was
adjusted to three times that required to produce maxi-
mum twitch tension. Maximum twitch tension was deter-
mined by averaging three sequential contractions.
Fatigue resistance was measured by stimulating muscle
with tetanic trains of pulses at a frequency of 50 Hz, last-
ing 330 ms. The tetanic trains were repeated once per sec-
ond for 2 minutes. The fatigue index was defined as the
ratio of the tension generated by a train at 2 minutes of
stimulation (T2) to the tension generated by the first train
in the test (T0). Thus, fatigue index = T2/T0. A single
tetanic train was produced each minute for 15 minutes
immediately after the continuous stimulation period, and
the force of the muscle contraction was recorded, so that
recovery of the muscle could be monitored. The limb was
considered fully recovered if the tension generated by a
single train in the recovery period (TR) was greater than
75% of the initial tension generated by the first train of the
fatigue test (fully recovered if TR ≥ 0.75 T0).
Measurements were made on both hindlimbs. The con-
tralateral normal hind limb served as an internal control.
After muscle stimulation, the rabbits were exsan-
guinated with a catheter in the common carotid artery and
killed with an overdose of ketamine and potassium chlo-
Table I. Revascularization scheme after creating an ischemic limb by ligating the right com-
mon iliac artery
Contralateral rectus 
muscle flap transposed onto 
Group thigh of ischemic limb Agent and site infused
Flap + bFGF Yes bFGF (3 ng/h), flap-thigh interface
Flap Yes Carrier solution, flap-thigh interface
bFGF No bFGF (3 ng/h), external iliac artery
Control No Carrier solution, external iliac artery
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ride. The pelvis and hindlimb tissues were perfusion fixed
with 1 L of 10% buffered formalin, infused at a pressure of
100 mm Hg through a 14-gauge catheter in the infrarenal
aorta. Bilateral soleus muscles were harvested and placed
in 10% formalin solution.
Blood vessel density. The harvested tissues were
dehydrated through a graded series of alcohol and paraffin-
embedded •••. Cross sections (6 µm thick) were cut at
the middle of the soleus muscle and immunostained for α-
actin antibody. This antibody recognizes only the α-actin
isoform of smooth muscle cells and does not react with
striated cardiac or skeletal muscles. Anti–α-actin antibodies
(Boehringer Mannheim Biotechnology, Indianapolis, Ind)
were applied in a 1:200 dilution, and the sections were
stained by means of the standard immunoperoxidase stain-
ing procedure with a commercial kit (Vectastain, Vecto
Laboratories, Burlingame, Calif) and counterstained with
hematoxylin and eosin. In our previous experience with
this rabbit model, the conventional endothelial markers,
factor VIII and various lectins, were nonspecific.15 The
most specific immunostaining was achieved against α-actin.
The slides were examined by an observer blinded to
the study groups with light microscopy. Blood vessels were
identified by tubular morphology with a single layer of
endothelial cells, the presence of intraluminal red blood
cells, and positive α-actin staining.15 Six random fields
were examined for each specimen, and the mean number
of vessels per high-power field was used.
Data analysis.All values are indexed to the contralat-
eral normal limb; thus, all values represent a ratio between
the ischemic limb and the contralateral normal limb.
Values are reported as mean ± one SEM. Maximum twitch
tension, the fatigue index, maximum recovery, and blood
vessel density were compared by means of one-way analy-
sis of variance with pairwise multiple comparisons with the
use of the Kruskal-Wallis method. Recovery of limbs was
analyzed with the Fisher exact test. A P value less than .05
was considered statistically significant.
RESULTS
Clinical assessment
On ligation of the right common iliac artery on day 0,
blood pressure was undetectable in the right hindlimb in
all animals. On day 7, blood pressure was undetectable in
all animals except one rabbit in the flap + bFGF group and
one in the control group.
On day 7, the weight of the soleus muscle of the
experimental limb was less than that of the contralateral
normal limb in all animals, but similar between groups
(flap + bFGF group = 0.88 ± 0.03, flap group = 0.82 ±
0.05, bFGF group = 0.80 ± 0.04, control group = 0.82 ±
0.04; P = .67).
Twenty-three of 26 rabbits had normal-appearing
hindlimbs and were able to bear weight and ambulate nor-
mally. In one rabbit from the flap + bFGF group and two
from the control group, the nails were black, ulcers were
present on the foot, and there was no motor function in
the ischemic limbs. On exploration, the muscles of the
entire limb were dead. In the rabbit from the flap + bFGF
group, this was associated with a thrombosed muscle flap.
These animals were excluded from further analysis.
Fig 3. Schematic diagram of muscle stimulation setup.
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Muscle stimulation
Contractile properties. The soleus muscle in the flap
+ bFGF group generated a twitch tension that was signifi-
cantly greater than that in the control animals (1.07 ± 0.13
vs 0.63 ± 0.12, P = .017). The flap, bFGF, and control
groups demonstrated similar twitch tension (Table II).
Fatigue and recovery. There was a trend toward a
higher fatigue index in the groups revascularized with a
muscle flap (flap + bFGF = 1.27 ± 0.08, flap = 0.90 ±
0.09, bFGF = 0.70 ± 0.09, controls = 0.72 ± 0.13; Table
II), but the differences were not significant.
Those groups with a transposed muscle flap (flap +
bFGF and flap groups) showed an increased capacity to
recover (Table II). The recovery in the flap + bFGF group
was significantly better than the bFGF and control Groups
(0.94 ± 0.05 vs 0.70 ± 0.07 and 0.58 ± 0.05, respectively;
P < .05). The flap group demonstrated increased recovery
compared with the control group (0.84 ± 0.05 vs 0.58 ±
0.05, respectively; P < .05). Maximum recovery for the
bFGF and control Groups was similar.
All ischemic limbs recovered to more than 75% of base-
line in the flap + bFGF group, which was significantly bet-
ter than the bFGF group (1/6 limbs recovered, P = .015)
and the control group (0/6 limbs recovered, P = .002).
Four of six ischemic limbs recovered in the flap group, but
this was not significantly better than the control group (P
= .06, Table II). The number of limbs fully recovered was
similar between the bFGF and control groups.
Blood vessel density. Ischemic limbs in the flap + bFGF
group demonstrated the greatest soleus blood vessel den-
sity, and this was significantly increased compared with the
flap, bFGF, and control groups (1.44 ± 0.11 vs 0.98 ±
0.03, 0.72 ± 0.19, and 0.72 ± 0.01, respectively; P < .05;
s II and III). The flap group had a significantly increased
density of blood vessels in the soleus muscle compared with
controls (0.98 ± 0.03 vs 0.72 ± 0.01, P < .05). The num-
ber of vessels in the bFGF and control groups was similar.
DISCUSSION
The most reliable treatment for limb-threatening
ischemia, arterial bypass grafting, is not possible in patients
who do not have a patent distal macroartery; these patients
ultimately require limb amputation. An alternative tech-
nique for limb salvage in patients with nonreconstructible
ischemic limbs is needed. Indirect revascularization with
omental flaps has not gained broad clinical acceptance,
despite some success 15 to 20 years ago.18-21 Recently,
however, indirect revascularization of ischemic limbs with
therapeutic angiogenesis has shown promise.10,11
In animal models of hindlimb ischemia, intramuscular
injections of endothelial cell growth factor, VEGF, and
bFGF led to increased collateral development, increased
capillary density, higher calf blood pressure, and improved
resting perfusion.1-5 Subcutaneous injections of acidic
FGF increased vascular density.9 Intravenous and intra-
arterial administration of VEGF resulted in increased calf
blood pressure and increased collateral formation and cap-
illary density.6,7 Naked DNA encoding for VEGF23,24 and
adenovirus-mediated VEGF gene transfer12 have also been
shown to stimulate angiogenesis.
These results led to phase I clinical trials in patients
who had critical limb ischemia, with intramuscular injec-
tions of naked VEGF complementary DNA directly into
ischemic muscle.10,11,22,25 The results in these small trials
Table II. Summary of results with direct muscle stimulation
Flap + bFGF (n = 6) Flap (n = 6) bFGF (n = 6) Control (n= 6)
Maximum twitch* 1.07 ± 0.13 0.80 ± 0.06 0.89 ± 0.14 0.63 ± 0.12
Fatigue index 1.27 ± 0.38 0.90 ± 0.09 0.70 ± 0.09 0.72 ± 0.13
Maximum recovery† 0.94 ± 0.05 0.84 ± 0.05 0.70 ± 0.07 0.58 ± 0.05
No. recovered‡ 5/5 4/6 1/6 0/6
No. vessels/HPF§ 1.44 ± 0.11 .98 ± 0.03 0.68 ± 0.13 0.65 ± 0.05
P < 0.05.
*Flap + bFGF versus control.
†Flap + bFGF versus bFGF, flap + bFGF versus control, flap versus control.
‡Flap + bFGF versus bFGF, flap + bFGF versus control.
§Flap + bFGF versus flap, flap + bFGF versus bFGF, flap
+ bFGF versus control, flap versus bFGF, flap versus
control.
bFGF, Basic fibroblast growth factor; HPF, •••.
Table III. Number of blood vessels per high-power field in the soleus muscle (raw data, mean ± SEM)
Flap + bFGF Flap bFGF Control
Ischemic (right) hindlimb 13.8 ± 1.3 9.2 ± 0.6 7.5 ± 1.2 7.5 ± 0.2
Normal (left) hindlimb 9.6 ± 0.7 9.3 ± 0.3 11.0 ± 0.7 10.3 ± 0.2
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have been equivocal. The fragile nature of naked plasmid
DNA and the abundant amount of natural deoxyribonu-
cleases in muscle may limit the effectiveness of this mode
of delivery.
The best method of administering angiogenic growth
factors is unknown. Furthermore, improvement in limb
function, the most clinically significant end point, has not
been previously assessed. This information must be deter-
mined before therapeutic angiogenesis becomes clinically
applicable.
A series of experiments based on a different model
have been performed in attempt to answer these ques-
tions. First, chronic hindlimb ischemia was established by
ligating and dividing the right common iliac artery. This
was shown to consistently reduce resting hindlimb perfu-
sion to 30% of baseline for at least 7 days.13 When a well-
perfused abdominal wall muscle flap was transposed to the
ischemic limb, new blood vessels developed, connecting
the arteries of the flap to the native circulation of the
limb.14,15 These new vessels increased the resting perfu-
sion of the ischemic limb by 45%.14 Local, continuous
infusion of bFGF (3 ng/h for 7 days) resulted in a twofold
increase in blood vessel density at the flap-thigh inter-
face.16 Finally, in this current study we evaluated the func-
tional outcome of an ischemic limb after revascularization
with a muscle flap, bFGF infusion, both, or neither.
This study demonstrated that revascularization of an
ischemic limb with a transposed muscle flap and local,
continuous infusion of bFGF-improved ischemic skeletal
muscle function, with a greater maximum force of con-
traction and improved recovery after continuous stimu-
lation, as well as a trend toward a higher resistance to
fatigue. Revascularization of an ischemic limb with a
muscle flap alone demonstrated slight improvement of
limb function (with respect to maximum recovery).
Also, reperfusion with continuous intra-arterial bFGF
infusion did not demonstrate any significant functional
improvement.
Limbs reperfused with a muscle flap and local infusion
of bFGF had a significantly greater blood vessel density in
the soleus muscle. Intra-arterial infusion of bFGF did not
increase the number of blood vessels in the calf. This is in
contrast to two studies performed at Tufts University, in
which an increased capillary density was noted after the
intramuscular injection of bFGF.3,4 It is possible that a
greater effect is achieved with intramuscular injection. The
bFGF receptors are ubiquitous on the endothelium; bFGF
may be quickly bound after arterial infusion, without
achieving an effect in the distal limb. Hopkins et al7 did
show an increased number of capillaries after treatment of
an ischemic limb with intra-arterial infusion of VEGF. The
difference between that and the current study may be due
to a specific difference between VEGF and bFGF.
The microvessel density in the soleus muscle was sig-
nificantly greater in the flap + bFGF group than in the
other groups, suggesting that muscle flap transposition
and local infusion of bFGF had a synergistic effect on
blood vessel density. Earlier experiments with this model
showed that blood vessels develop and connect the circu-
lation of the flap with the circulation of the ischemic
limb,14 that new proliferating vessels form in the interface
between the flap and the limb,15 and that local infusion of
bFGF at the flap-limb interface leads to a doubling of the
number of these vessels.16 Whether the increased density
of blood vessels in the soleus muscle represents direct con-
nection with the vessels forming at the flap-limb interface
or is the result of a “downstream” effect of improved per-
fusion could not be determined in the current study.
This study suggests that the combination of transfer of
well-perfused muscle with local infusion of bFGF results in
greater improvement in the function of ischemic skeletal
muscle than the use of simple intra-arterial infusion of
bFGF. This alone may be enough to justify the greater
complexity of tissue transfer with local bFGF infusion, ver-
sus simpler techniques of delivery of angiogenic growth
factors, for attempted clinical limb salvage. However,
there are other theoretical advantages. In most patients
with limb-threatening ischemia, there are multiple levels
of arterial occlusion. For the achievement of limb salvage
with simple delivery of angiogenic factors or their genetic
material, collateral arteries would need to develop across
all levels of occlusion, a process that would be expected to
require some time. Tissue transfer could allow the imme-
diate provision of a source of new arterial supply directly
to the level of maximal ischemia. For example, a patient
with ischemic rest pain of the foot with popliteal and tib-
ial arterial occlusive disease could have a free flap trans-
ferred onto the foot with local infusion of bFGF at the
flap-tissue interface. New blood vessels would be expected
to invade the ischemic tissue within 7 days and to poten-
tially and incrementally improve the perfusion enough to
avoid tissue death, a process that often progresses rapidly.
Previous work showed histologically demonstrable vessels
at the flap-limb interface,15 and angiographic connections
between the flap and native arteries,14 at 7 days. The cur-
rent study showed improved function of ischemic muscle
at 7 days.
Limb blood pressure did not improve in any of the
groups over the 7-day study. This is consistent with prior
experiments in which this model was used, where limb
blood pressure did not improve, despite a 45% increase in
the resting limb muscle perfusion14 and despite a 100%
increase in the number of vessels at the flap-limb inter-
face.16 The blood pressure measurements were used to
confirm ligation of the right common iliac artery and to
demonstrate the persistent insufficiency of macroarterial
circulation. The functional recovery in these limbs at 7
days is apparently due to improvement in the microcircu-
lation, not the development or dilatation of large caliber,
low-resistance macroarteries that would be expected to
improve the blood pressure.
It is possible that the study groups did not have iden-
tical arterial insufficiency. In the flap groups, the right
common iliac artery was ligated and divided. In the
groups with intra-arterial infusion, the right common iliac
artery was ligated proximally, and the infusion catheter
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was inserted through an arteriotomy in the common iliac
artery distal to the ligature, with the tip of the catheter
positioned in the proximal external iliac artery. It is possi-
ble that the catheter decreased blood flow in the external
iliac and internal iliac arteries to a greater extent than that
in the animals without an intra-arterial infusion catheter.
Another potential limitation to this study is the short
duration of follow-up. With this study, no conclusion on
the duration of effects on limb function beyond 1 week
can be made.
CONCLUSIONS
Reperfusion of an ischemic limb with a well-vascular-
ized muscle flap and local bFGF infusion promoted
increased blood vessel density in distal ischemic muscle.
This increased vascular density was associated with restora-
tion of otherwise impaired muscle function. Furthermore,
improved function occurred rapidly (1 week), suggesting
that a transposed muscle flap provides a functional blood
supply to sites of maximum ischemia and may be used to
help salvage otherwise nonreconstructible ischemic limbs.
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